CTSA Supplement
CTSA 补充
基本信息
- 批准号:9250940
- 负责人:
- 金额:$ 11.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-18 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAcademyAccident and Emergency departmentAddressAdoptedAdvocacyAfrican AmericanAgingAppointmentAreaAromatic Polycyclic HydrocarbonsAwardBed OccupancyBedsBioinformaticsBiological SciencesBudgetsBurn injuryCaringCatchment AreaChildhoodClinicClinicalClinical ResearchClinical ServicesClinical TrialsCommunitiesCommunity Health EducationCommunity HealthcareCourse ContentDay SurgeryDengueDevelopmentDevicesDisastersDiscipline of NursingDiverse WorkforceEbola virusEducationEducational CurriculumEntrepreneurshipEnvironmentEnvironmental HealthEnvironmental MedicineEthicsEvaluationFacultyFosteringFrankfurt-Marburg Syndrome VirusFundingFunding OpportunitiesGeriatricsGoalsGood Clinical PracticeGrantGrowthHealthHealth OccupationsHealth PersonnelHealth SciencesHealth systemHealthcareHispanicsHistorically Black Colleges and UniversitiesHome environmentHospital ReferralsHospitalsHumanHybridsImmunityImpact evaluationIndividualIndustryInfectionInpatientsInstitute of Medicine (U.S.)InstitutesInstitutionInvestmentsIslandKnowledgeLaboratoriesLatinoLeadershipLongitudinal StudiesMedicalMethodsMissionModelingMolecularMonitorMulti-Institutional Clinical TrialNational Institute of Allergy and Infectious DiseaseOilsOutcomeOutcomes ResearchOutpatientsParasitic DiseasesParticipantPatient AdmissionPatient CarePatient-Focused OutcomesPatientsPatients&apos RoomsPediatricsPharmacy facilityPhasePopulationPositioning AttributePregnancyProcessPublic PolicyPublishingPuerto RicoRadialRecommendationReportingResearchResearch ActivityResearch InfrastructureResearch InstituteResearch PersonnelResearch Project GrantsResearch SupportResource SharingResourcesRoleSatellite HospitalsScheduleSchoolsScienceScientistServicesSiteSpecial Populations ResearchStagingStudentsSystemTeaching HospitalsTestingTexasTherapeuticTrainingTraining SupportTranslational ResearchTranslationsUnderrepresented MinorityUnited States National Institutes of HealthUniversitiesVaccinesViral Hemorrhagic FeversVirus DiseasesVisionVisitWagesWingWorkWorkforce Developmentabstractingbasebed capacitybench to bedsidecareercohortcollaborative environmentcommercializationcommunity based participatory researchcomparative effectivenessdata sharingeffectiveness researchevidence baseexperiencegulf coastimplementation researchimprovedinnovationinter-institutionalinterestleadership developmentlearning communitymedical schoolsmedical specialtiesmembermultidisciplinarynamed groupnovelnovel diagnosticsnovel strategiesoutreachpathogenpatient advocacy grouppatient populationprogramsquality assuranceresearch clinical testingresearch facilityresponsescience educationskillssquare foottertiary caretherapeutic vaccinetooltranslational studytrauma centersvaccine developmentworking group
项目摘要
Contact PD/PI: Brasier, Allan R.
The CTSA at the University of Texas Medical Branch (UTMB) is located within the Institute for Translational
Science (ITS), one of three free-standing UTMB institutes, established in 2007. In its role as the home for
clinical and translational research, the ITS provides primary tenure-earning faculty appointments to 7 early-
career translational scientists. Over the past 5½ years, we have transformed UTMB's research culture, growing
from an institution that solely valued individual laboratory-oriented research to one that embraces
multidisciplinary translational team (MTT) approaches to addressing significant health problems. We have
developed novel educational curricula, significant clinical research programs in special populations with multi-
site clinical trials (CTs), and provided leadership in the Texas Regional CTSA consortium (TRCC) and
nationally. The mission of the UTMB CTSA hub is to support the health goals of the nation by
generating, testing and disseminating integrative team science, education and best practices through
stakeholder involvement at all stages. Managed by a continuous improvement model using an Innovation
Scorecard, the UTMB CTSA will address four specific aims, to: 1) Train a diverse workforce in the authentic
skills needed to advance all phases of translational research. We have used the team environment as an
educational framework to support the training of diverse learning communities. Our innovation,
entrepreneurship, and team leadership curricula will be used to instill focused, career stage-appropriate
competencies in our trainees. We have led in sharing and disseminating innovative educational content in
entrepreneurship and team science throughout the consortium. 2). Engage stakeholders across all phases
of translational research and CTs. We will extend our substantial bidirectional interactions with stakeholders
from the community, patient advocacy groups, healthcare providers and our Health System to assess health
needs, set CTSA priorities and disseminate competencies. 3). Integrate quality systems through all types
of translational research, including CTs in special populations. We have provided leadership to a
university-wide plan for sustainable support for high-quality CTs through the Office of Clinical Research,
supported by an experienced director, an interoperable Clinical Trial Management System and staff to provide
streamlined support for all phases of CT start-up, quality assurance monitoring, study management and GCP
training. 4). Advance the conduct of translational research through MTT-based innovation. The UTMB
CTSA hub is unique in the national consortium in its systematic application of a hybrid industry-academic MTT
model, and have developed an evidence base on the formation, evaluation, impact and trajectories of
successful MTTs. We will stimulate MTT innovation by promoting team development, leadership development
by a unique Leadership Development Academy, and advancement of therapeutics and devices into Phase I/II
CTs in our “Innovations in Molecular Therapeutics and Devices” Optional Module.
Project Summary/Abstract Page 308
Contact PD/PI: Brasier, Allan R.
Narrative
The UTMB CTSA hub will support bidirectional translational research, moving discoveries from the bench to
the bedside, by training a capable workforce using our unique multidisciplinary translational teams and
innovative educational programs that build real-world skills. Our hub will serve to foster high-quality clinical
research, develop best practices in team-based translations, participate in inter-institutional data-sharing, and
function as an efficient site for multi-site clinical trials in understudied populations. In this manner, the UTMB
CTSA hub will be an important contributor to achieving the goals of the national consortium.
联系人 PD/PI:Brasier, Allan R.
德克萨斯大学医学分部 (UTMB) 的 CTSA 位于转化研究所内
Science (ITS) 是三个独立的 UTMB 机构之一,成立于 2007 年。
临床和转化研究方面,ITS 为 7 名早期获得终身教职的教员提供了任命
在过去的 5.5 年里,我们改变了 UTMB 的研究文化,不断发展。
从一个只重视个人实验室导向研究的机构转变为一个包含
我们拥有解决重大健康问题的多学科转化团队 (MTT) 方法。
开发了新颖的教育课程,针对特殊人群的重要临床研究项目,具有多种
现场临床试验 (CT),并在德克萨斯州地区 CTSA 联盟 (TRCC) 和
UTMB CTSA 中心的使命是通过以下方式支持国家的健康目标。
通过以下方式生成、测试和传播综合团队科学、教育和最佳实践
通过使用创新的持续改进模型来管理所有阶段的利益相关者参与。
根据记分卡,UTMB CTSA 将实现四个具体目标,即: 1) 在真实的环境中培训多元化的劳动力
推进转化研究各个阶段所需的技能我们利用团队环境作为一个平台。
支持多元化学习社区培训的教育框架。
创业和团队领导课程将用于灌输专注的、适合职业阶段的课程
我们在分享和传播创新教育内容方面发挥了主导作用。
整个联盟的创业精神和团队科学 2)。
我们将扩大与利益相关者的实质性双向互动。
来自社区、患者倡导团体、医疗保健提供者和我们的卫生系统的健康评估
需求,设定 CTSA 优先事项并传播能力 3)。
转化研究,包括特殊人群的 CT 研究,我们提供了领导。
通过临床研究办公室为高质量 CT 提供可持续支持的全校范围计划,
由经验丰富的主管、可互操作的临床试验管理系统和工作人员提供支持,以提供
简化对 CT 启动、质量保证监测、研究管理和 GCP 所有阶段的支持
4). 通过基于 MTT 的创新来推进转化研究。
CTSA 中心在行业-学术混合 MTT 的系统应用方面在国家联盟中是独一无二的
模型,并开发了关于形成、评估、影响和轨迹的证据基础
成功的 MTT。我们将通过促进团队发展、领导力发展来刺激 MTT 创新。
通过独特的领导力发展学院,并将疗法和设备推进到 I/II 期
我们的“分子治疗和设备创新”可选模块中的 CT。
项目总结/摘要第 308 页
联系人 PD/PI:Brasier, Allan R.
叙述
UTMB CTSA 中心将支持双向转化研究,将实验室的发现转移到实验室
在床边,通过使用我们独特的多学科翻译团队培训有能力的员工队伍,
我们的中心将致力于培养高质量的临床技能的创新教育计划。
研究、开发团队翻译的最佳实践、参与机构间数据共享,以及
通过这种方式,UTMB 成为在受研究人群中进行多中心临床试验的有效场所。
CTSA 中心将成为实现国家联盟目标的重要贡献者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Allan R. Brasier其他文献
Modulation of Gene Expression Regulated by NFkB/RelA
NFkB/RelA 调节基因表达
- DOI:
doi:10.1074/jbc.m113.539965 - 发表时间:
2014 - 期刊:
- 影响因子:4.8
- 作者:
Xueling Li;Yingxin Zhao;Bing Tian;Mohammad Jamaluddin;Abhishek Mitra;Jun Yang;Maga Rowicka;Allan R. Brasier;Andrzej Kudlicki - 通讯作者:
Andrzej Kudlicki
Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines.
萤火虫荧光素酶测定作为哺乳动物细胞系报告基因的优化使用。
- DOI:
- 发表时间:
1989-11-01 - 期刊:
- 影响因子:2.7
- 作者:
Allan R. Brasier;James E. Tate;J. Habener - 通讯作者:
J. Habener
Differentiation-specific element: a cis-acting developmental switch required for the sustained transcriptional expression of the angiotensinogen gene during hormonal-induced differentiation of 3T3-L1 fibroblasts to adipocytes.
分化特异性元件:在激素诱导的 3T3-L1 成纤维细胞向脂肪细胞分化过程中,血管紧张素原基因持续转录表达所需的顺式作用发育开关。
- DOI:
- 发表时间:
1993 - 期刊:
- 影响因子:0
- 作者:
Robert E. McGehee;David Ron;Allan R. Brasier;J. Habener - 通讯作者:
J. Habener
Angiotensinogen gene-inducible enhancer-binding protein 1, a member of a new family of large nuclear proteins that recognize nuclear factor kappa B-binding sites through a zinc finger motif
血管紧张素原基因诱导增强子结合蛋白 1,是大核蛋白新家族的成员,可通过锌指基序识别核因子 kappa B 结合位点
- DOI:
- 发表时间:
1991 - 期刊:
- 影响因子:5.3
- 作者:
David Ron;Allan R. Brasier;J. Habener - 通讯作者:
J. Habener
Two-dimensional peptide mapping of fibronectins from bovine aortic endothelial cells and bovine plasma.
牛主动脉内皮细胞和牛血浆纤连蛋白的二维肽图谱。
- DOI:
10.1016/0006-291x(80)90302-2 - 发表时间:
1980-11-28 - 期刊:
- 影响因子:3.1
- 作者:
Charles R. Birdwell;Allan R. Brasier;Lorna A. Taylor - 通讯作者:
Lorna A. Taylor
Allan R. Brasier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Allan R. Brasier', 18)}}的其他基金
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
- 批准号:
10495267 - 财政年份:2021
- 资助金额:
$ 11.63万 - 项目类别:
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
- 批准号:
10373575 - 财政年份:2021
- 资助金额:
$ 11.63万 - 项目类别:
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma
过敏性哮喘粘膜抗病毒免疫的表观遗传机制重编程
- 批准号:
10553704 - 财政年份:2019
- 资助金额:
$ 11.63万 - 项目类别:
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma
过敏性哮喘粘膜抗病毒免疫的表观遗传机制重编程
- 批准号:
10371977 - 财政年份:2019
- 资助金额:
$ 11.63万 - 项目类别:
Transcriptional Elongation in NF-kB Mediated Inflammation
NF-kB 介导的炎症中的转录延伸
- 批准号:
8710493 - 财政年份:2013
- 资助金额:
$ 11.63万 - 项目类别:
相似国自然基金
“抗疫精神”对医护职业偏好、行为偏好的短期与长期影响:基于医务人员和医学院学生的研究
- 批准号:72173093
- 批准年份:2021
- 资助金额:48 万元
- 项目类别:面上项目
湖州师范学院理论物理强子共振态和核物理方向学术交流与平台建设
- 批准号:
- 批准年份:2021
- 资助金额:50 万元
- 项目类别:
湖州师范学院理论物理奇特核结构与反应方向学术交流与平台建设
- 批准号:
- 批准年份:2020
- 资助金额:50 万元
- 项目类别:专项基金项目
数学院士专家大学中学系列科普活动
- 批准号:12026425
- 批准年份:2020
- 资助金额:20.0 万元
- 项目类别:数学天元基金项目
湖州师范学院基于HIRFL-CSR和HIAF的核物理理论发展和交流平台
- 批准号:
- 批准年份:2019
- 资助金额:50 万元
- 项目类别:专项基金项目
相似海外基金
UNderstanding the Delivery of Low-Value CAre To CHildren and the Barriers to De-Implementation (UN-LATCH)
了解向儿童提供低价值护理以及取消实施的障碍 (UN-LATCH)
- 批准号:
10649811 - 财政年份:2023
- 资助金额:
$ 11.63万 - 项目类别:
ED-LEAD: Emergency Departments LEading the transformation of Alzheimer's and Dementia care
ED-LEAD:急诊科引领阿尔茨海默病和痴呆症护理的变革
- 批准号:
10709334 - 财政年份:2023
- 资助金额:
$ 11.63万 - 项目类别:
Using video games to increase implementation of clinical practice guidelines in trauma triage
使用视频游戏加强创伤分诊临床实践指南的实施
- 批准号:
10582783 - 财政年份:2023
- 资助金额:
$ 11.63万 - 项目类别: